EBITDA: Income before interest, taxes, depreciation and amortization.
Dermata Therapeutics, Inc. (DRMA) had EBITDA of $-7.77M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.56M |
|
-- |
|
-- |
|
$7.77M |
|
$-7.77M |
|
$0.21M |
|
$-7.56M |
|
$-7.56M |
|
$-7.56M |
|
$-7.56M |
|
$-7.56M |
|
$-7.56M |
|
$-7.77M |
|
|
EBITDA |
$-7.77M |
0.93M |
|
0.93M |
|
$-8.16 |
|
$-8.16 |
|
| Balance Sheet Financials | |
$7.86M |
|
-- |
|
-- |
|
$7.86M |
|
$1.64M |
|
-- |
|
-- |
|
$1.64M |
|
$6.22M |
|
$6.22M |
|
$6.22M |
|
2.66M |
|
| Cash Flow Statement Financials | |
$-7.76M |
|
-- |
|
$12.12M |
|
$3.16M |
|
$7.52M |
|
$4.36M |
|
$0.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.76M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-121.45% |
|
-121.45% |
|
-96.12% |
|
-121.45% |
|
$2.34 |
|
$-8.38 |
|
$-8.38 |
|